Literature DB >> 18371067

Itraconazole affects Toxoplasma gondii endodyogeny.

Erica Dos Santos Martins-Duarte1, Wanderley de Souza, Rossiane Claudia Vommaro.   

Abstract

The antifungal agent itraconazole is an effective drug against systemic mycoses inhibiting cytochrome P-450-mediated ergosterol synthesis, essential for fungal survival. In this work, we show the activity of this azole as a potential agent against Toxoplasma gondii, the causative agent of toxoplasmosis. Monolayers of LLC-MK2 epithelial cells infected with tachyzoites of RH strain were incubated with different concentrations of itraconazole for 24 and 48 h. The IC(50) values obtained were 114.0 and 53.6 nM for 24 and 48 h, respectively. Transmission electron microscopy (TEM) analysis of itraconazole-treated intracellular tachyzoites showed endoplasmic reticulum and nuclear envelope swelling. The drug also caused rupture of the parasite's surface membrane and affected the parasite's division by endodyogeny. This observation was confirmed both by fluorescence microscopy of cells labeled with diamidino-2-phenylindole and by three-dimensional reconstruction of serial thin sections analyzed by TEM. The treatment with itraconazole led to the formation of a mass of daughter cells, suggesting the interruption of the scission process during the parasite's cell division.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371067     DOI: 10.1111/j.1574-6968.2008.01130.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  12 in total

Review 1.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  The benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme target.

Authors:  Craig Wilkinson; Martin J McPhillie; Ying Zhou; Stuart Woods; Gustavo A Afanador; Shaun Rawson; Farzana Khaliq; Sean T Prigge; Craig W Roberts; David W Rice; Rima McLeod; Colin W Fishwick; Stephen P Muench
Journal:  Bioorg Med Chem Lett       Date:  2013-12-22       Impact factor: 2.823

3.  Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.

Authors:  Loyze Paola O de Lima; Sergio H Seabra; Henrique Carneiro; Helene S Barbosa
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

4.  Synthesis and Biological Activity of Novel Zinc-Itraconazole Complexes in Protozoan Parasites and Sporothrix spp.

Authors:  Jose Aleixo de Azevedo-França; Renato Granado; Sara Teixeira de Macedo Silva; Gabrielle Dos Santos-Silva; Sandra Scapin; Luana P Borba-Santos; Sonia Rozental; Wanderley de Souza; Érica S Martins-Duarte; Emile Barrias; Juliany Cola Fernandes Rodrigues; Maribel Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

5.  Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii.

Authors:  Erica S Martins-Duarte; Faustine Dubar; Philippe Lawton; Cristiane França da Silva; Maria de Nazaré C Soeiro; Wanderley de Souza; Christophe Biot; Rossiane C Vommaro
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

6.  Data on (+)-usnic acid: A new application to treat toxoplasmosis.

Authors:  Kaiwei Si; Linlin Wei; Xiaozhuo Yu; Feng Wu; Xiaoqi Li; Chen Li; Yanbin Cheng
Journal:  Data Brief       Date:  2016-06-18

7.  Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.

Authors:  Yuho Murata; Tatsuki Sugi; Louis M Weiss; Kentaro Kato
Journal:  PLoS One       Date:  2017-06-13       Impact factor: 3.240

Review 8.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

Review 9.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

10.  Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.

Authors:  Sekandarpour Sina; Jafari Modrek Mohammad; Shafiei Reza; Mohammadiha Anita; Etemadi Soudabeh; Mirahmadi Hadi
Journal:  Eur J Med Res       Date:  2021-06-30       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.